Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Developmental Biology

Open Access

Identification of the heart as the critical site of adenosine mediated embryo protection

  • Christopher C Wendler1Email author,
  • Ryan R Poulsen1,
  • Satish Ghatpande1,
  • Robert W Greene2 and
  • Scott A Rivkees1
BMC Developmental Biology201010:57

https://doi.org/10.1186/1471-213X-10-57

Received: 19 March 2010

Accepted: 28 May 2010

Published: 28 May 2010

Abstract

Background

Our understanding of the mechanisms that protect the developing embryo from intrauterine stress is limited. Recently, adenosine has been demonstrated to play a critical role in protecting the embryo against hypoxia via adenosine A1 receptors (A1ARs), which are expressed in the heart, nervous system, and other sites during development. However, the sites of A1AR action that mediate embryo protection are not known. To determine if the heart is a key site of adenosine-mediated embryo protection, A1ARs were selectively deleted in the embryonic heart using a Cre-LoxP system in which the alpha-myosin heavy chain promoter drives Cre-recombinase expression and excision of the A1AR gene from cardiomyocytes.

Results

With increasing exposure of maternal hypoxia (10% O2) from 48-96 hours beginning at embryonic day (E) 8.5, embryo viability decreased in the cardiac-A1AR deleted embryos. 48 hours of hypoxia reduced embryonic viability by 49% in embryos exposed from E10.5-12.5 but no effect on viability was observed in younger embryos exposed to hypoxia from E8.5-10.5. After 72 hours of hypoxia, 57.8% of the cardiac-A1AR deleted embryos were either dead or re-absorbed compared to 13.7% of control littermates and after 96 hours 81.6% of cardiac-A1AR deleted embryos were dead or re-absorbed. After 72 hours of hypoxia, cardiac size was reduced significantly more in the cardiac-A1AR deleted hearts compared to controls. Gene expression analysis revealed clusters of genes that are regulated by both hypoxia and A1AR expression.

Conclusions

These data identify the embryonic heart as the critical site where adenosine acts to protect the embryo against hypoxia. As such these studies identify a previously unrecognized mechanism of embryo protection.

Background

Hypoxia is a common fetal stressor that can be caused by placental insufficiency, maternal smoking, anemia, cord compression, preeclampsia, and living at high altitude [1]. Increasing evidence indicates that hypoxia can have profound effects on embryogenesis and influence cardiac development [2, 3]. Hypoxic exposure of chicken embryos for the first 3.5 days (an equivalent of embryonic day (E) 10.5 in mouse), leads to reduced embryonic viability, growth inhibition, and altered cardiac function [4]. Long exposure to hypoxia later in development also effects cardiac development, heart function and leads to dilated cardiomyopathy [5]. Fetal hypoxia in mammals results in intrauterine growth retardation and reduced birth weight [1, 6]. We also observe that hypoxia disproportionately reduces cardiac growth in embryos [3].

Evidence indicates that adenosine plays important role mediating effects of hypoxia during development [2, 3, 7]. Adenosine levels are dynamically regulated and increase markedly in hypoxia [8]. Adenosine acts through specific G protein-coupled receptors, including A1 adenosine receptors (A1ARs), which are activated by slight increases in adenosine levels [9, 10]. A1ARs are expressed in cardiac tissue very early in embryogenesis and can regulate fetal heart function [11, 12]. A1ARs are expressed in the myocardium of developing hearts beginning at E8 and cardiac A1AR expression continues throughout development [12]. In adults, over-expression of A1ARs protects the heart from ischemic/reperfusion injury, and the loss of A1ARs impairs ischemic tolerance [13, 14].

We previously demonstrated that A1ARs play an essential role in protecting the embryo from hypoxia [3]. Whereas A1AR-deficient embryos do not display birth defects or growth restriction under normoxic conditions [15], embryos with global deletion of A1ARs (A1AR-/-) are severely growth retarded and have reduced viability [3]. In addition, A1AR-/- embryos expressed less stabilized hypoxia-inducible factor 1α (HIF1α) protein under hypoxic conditions and have abnormal patterns of embryonic gene expression [3]. Because A1ARs were deleted from all embryonic tissues in those studies, it was not possible to localize the embryo-protective sites of A1AR action.

During embryogenesis, A1ARs are expressed in the nodal region, the heart, and the nervous system [12]. It is also likely that A1ARs are expressed in other sites that have eluded localization via methods that have been applied. After E9.0, the embryo is dependent on the fetal heart for adequate nutrient delivery [16]. Thus isolated effects on the developing heart could induce global effects on the embryo after E9.0. To test this hypothesis, we examined the role of cardiac A1ARs in mediating embryonic protection against hypoxia through the use of a mouse model in which A1ARs are deleted in the heart, using the Cre/loxP system, with Cre-recombinase expression driven by an alpha-myosin heavy chain (α-MHC) promoter [17]. We now report that the heart is the major site where A1AR acts to confer protection against intrauterine hypoxia.

Methods

Animals

All experiments approved by the Institutional Animal Care and Use Committee (IACUC) of Yale University. Mice lacking cardiac A1ARs were generated by homologous recombination to introduce loxP sites around the major coding exon of the A1AR gene [18]. Cre-recombinase expression produces a truncated and non-functional A1AR gene by excising the DNA sequence between loxP sites [18]. Cardiomyocyte-specific A1AR knockout mice were generated by crossing A1AR-loxP mice with αMHC-Cre mice. A1AR-loxP (floxed; A1ARfl/fl) mice were generated and provided by Dr. R. Greene (Southwestern University, Dallas TX) [18]. α-MHC-Cre mice were provided by Dr. M. Schnieder (Baylor Medical Center, Houston, TX). αMHC and Cre-transgenes are expressed in the developing myocardium beginning at E7.5 [17, 19].

To generate mice with A1ARs deleted from cardiomyocytes, αMHC-Cre mice were bred with A1ARfl/fl mice. Male αMHC-Cre mice were mated with female mice homozygous for the A1AR floxed allele (A1ARfl/fl). The F2 matings were A1ARfl/+, αMHC-Cre × A1ARfl/fl, from which A1ARfl/fl, αMHC-Cre males were mated with A1ARfl/fl females to produce the embryos used in these experiments. This mating scheme produces litters with embryos expressing A1ARs in the heart and embryos without cardiac A1ARs.

Genomic DNA was isolated from tail biopsies or embryonic yolk sacs with the DNeasy Tissue Kit from Qiagen (Valencia, CA) [20]. Genotyping PCR was performed on genomic DNA to confirm animals were A1ARfl/fl and determine if αMHC-Cre was present. The presence of the A1AR floxed allele was confirmed when the forward primer (GATCCGCAAGCAGCTCAACAAA) and reverse primer (AAACTCCTCTTCAGACCTAATAAC) yielded a 619 bp band. The absence of the wild type allele was assessed with the forward primer (TGTCCTCTTCCCTTCCTGCTCCATGATTACCA) and reverse primer (AGAGACAGCGAAGCGGCGGCATATCCATTT), which yielded a 2413 bp band if the wild type allele is present. The presence of αMHC-Cre was confirmed when the forward primer (CGATGCAACGAGTGATGAGG) and reverse primer (CGCATAACCAGTGAAACAGC) yielded a 300 bp band.

Radioreceptor Assay

To verify deletion of A1AR expression, radioreceptor assays were performed, as described [12]. Radioreceptor assays were performed on hearts and brains of postnatal day (P) 7 mouse pups using the A1AR-selective ligand [3H]DPCPX (1-3, dipropylcyclopentyl xanthine) [12]. Because of the small sizes of the embryos, it was not possible to assess embryonic cardiac expression.

In uteroHypoxia

Pregnant mice were used to examine the effects of hypoxia on embryos, as described [3, 21]. Hypoxia has been reported to increase the concentration of adenosine in the circulation to 2 μM in fetal sheep [22]; however, due to the small size of the murine embryos we were unable to determine embryonic levels of adenosine. Timed matings were used to obtain the appropriate stage embryos, with embryonic (E) day 0.5 designating the day a vaginal plug was observed. Pregnant dams were placed in a Plexiglass chamber (Biospherix, Redfield, NY) equipped with an oxygen sensor that maintains ambient O2 levels between 9.5-10.5% by introducing 100% medical grade nitrogen into the chamber [20]. This level of oxygen was selected because pregnant dams tolerate this concentration, and it has adverse effects on embryogenesis [3, 23]. In a previous report, we validated this protocol using Hypoxyprobe-1 [3]. These experiments demonstrated that the partial pressure of oxygen (pO2) in embryonic tissue was less than 10 mm Hg or less than 1.3% O2 [3]. Control animals were housed in the same room as the hypoxia chamber in room air (21% O2). Pregnant dams were housed in the chamber for 48-96 hours.

Embryo Morphology Analysis

At the end of hypoxia or normoxia exposure, pregnant dams were immediately euthanized with 100% CO2. Embryos were collected in Dulbecco's phosphate buffered saline (D-PBS, Invitrogen, Carlsbad, CA) and assessed for viability. Embryos with beating hearts were scored as alive; embryos without beating hearts were scored as dead; when no embryo was collected from a uterine bud, it was scored as reabsorbed. The viability rate was calculated as the number of live embryos divided by the total number of embryos collected, including dead and reabsorbed.

Embryonic and cardiac morphology was assessed using a Zeiss Stemi 2000-C dissecting microscope (Carl Zeiss, Oberkochen, Germany). Digital images of whole embryos were captured with an Olympus C-5060 camera (Olympus, Tokyo, Japan). Quantitative measurements of the crown-rump (CR) length were taken from photographic prints.

Embryos were fixed, embedded in paraffin, and sectioned, as described [24]. Sections were stained with Harris-modified hematoxylin and Eosin Y (H&E, Fisher Scientific, Fair Lawn, NJ), according to standard procedures. Images were captured under bright field conditions with an Olympus IX70 inverted microscope and analyzed for cross sectional area of various cardiac structures using Image-Pro Plus analysis software (Media Cybernetics, Inc., Silver Spring, MD). Area analysis was taken from sagittal sections of embryos at the level of the junction of the atrioventricular (AV) canal and the ventricle. The area of the ventricular myocardium, AV canal cushions or outflow tract (OFT) cushions were outlined and the area determined by imaging software. Every third section was analyzed, and 5-6 sections per embryo were quantitated. The average area for each cardiac structure was determined for each embryo.

Microarray Analysis

Total RNA was purified from isolated hearts exposed to in utero hypoxia (10% O2) for 24 hours from E9.5 to E10.5, as described [3]. RNA was collected from at least 10 hearts from each group (Normox/Flox, Normox/Cre, Hypox/Flox, and Hypox/Cre). The RNA was then provided to the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale University for analysis. Gene expression analysis was performed using the Illumina microarray gene chip Mouse 6 (Illumina Inc., San Diego, CA), which interrogates the whole mouse genome of over 30,000 genes. Each analysis was run in triplicate. Changes in gene expression (fold change) and p-values were calculated using Partek software (St. Louis, MO) at the Yale Center for Statistical Genomics and Proteomics. Analysis of gene pathways was performed using Metacore software (Genego Pathway Analysis Inc., San Diego, CA).

Statistical Analysis

Data are presented as means +/- the standard error of the mean (SEM). Analyses were performed with the statistics software package included with Microsoft Excel (Microsoft, Edmond, WA) and GraphPad Prism (GraphPad Software Inc., San Diego, CA). Statistical comparisons between groups were performed with student t tests (two sample assuming equal variances), ANOVA, or the Mann-Whitney test. P < 0.05 was considered to be statistically significant.

Results

Deletion of cardiac A1ARs results in reduced embryonic viability in hypoxia

We first verified deletion of A1AR expression in the heart by radioreceptor assay [12], using the A1AR-selective ligand [3H]DPCPX (1-3, dipropylcyclopentyl xanthine) [12]. In the A1ARfl/fl mice, the concentration of A1ARs in brain and heart were 28.2 + 4.2 and 2.2 + 1.1 fmol/mg of protein, respectively. However, in the A1ARfl/fl, αMHC-Cre mice, concentrations of A1ARs in brain and heart were 29.7 + 3.0 and 0.0 + 0.0 fmol/mg of protein, respectively. Thus, there is no A1AR expression in the hearts of the A1ARfl/fl, αMHC-Cre mice.

To examine the role of cardiac A1ARs in protecting the developing embryo from hypoxia, pregnant dams were exposed to hypoxia for 48, 72, or 96 hours. We first examined the viability of embryos following hypoxic exposure. Each embryo or uterine bud was scored as either alive (heart beating), dead (embryo intact but no beating heart), or reabsorbed (no recognizable tissue inside a uterine bud.

When pregnant dams were treated for 48 hours from E8.5 to E10.5, there were no significant differences between normoxia (room air) and hypoxia (10% O2) exposure in the percentage of live embryos (Fig. 1A). The viability (percentage of live embryos) for the 48 hours groups was 86.4% (51 alive out of 59 total embryos) for normoxia and 81.3% (39/47) for hypoxia treatment groups, respectively. These percentages are consistent with what we observed for all normoxia groups examined, and ranged from 80-90% viability.
Figure 1

Cardiac specific knockout of A1AR reduces embryonic viability under hypoxic conditions. Pregnant dams were reared in room air or hypoxia (10% O2) for 2, 3, or 4 days beginning at E8.5. (A) 2-day treatment from E8.5-10.5, no difference in viability between normoxia and hypoxia, P > 0.05. (B) 3-day treatment from E8.5-11.5, hypoxia induced a decrease in viability of 52% in the A1AR cardiac-specific knockout mice but not in the normal A1AR expressing (Hypoxia +/+) litters. (C) 4-day treatment from E8.5-12.5, hypoxia caused a greater reduction in viability of 78% compared to normoxia controls. In addition, 2-day treatment from E10.5-12.5 induced a significant decrease in viability of 40% that was not seen in the younger 2-day treated (E8.5-10.5) embryos. *, P ≤ 0.05 by Mann-Whitney test with a 99% confidence level.

We next examined effects of 72 hours of hypoxic exposure in utero, from E8.5-11.5. 88.1% (82/93) of embryos in normoxic dams were viable, and 42.2% (35/83) were viable in the hypoxia-exposed dams (Fig. 1B). This decrease in viability was reflected in an increase in the number of dead embryos and an increase in the number of reabsorbed embryos (Fig. 1B). The low level of dead embryos 4.3% (4/93) and reabsorbed embryos 7.5% (7/93) in room air increased to 28.9% (24/83) for both dead and reabsorbed embryos after 72 hours of hypoxia (Fig. 1B).

To confirm that reduced viability was due to the loss of cardiac A1ARs, A1ARfl/fl females were mated with A1ARfl/fl males without the Cre-recombinase gene. When we examined the litters from A1ARfl/fl matings exposed to 72 hours of hypoxia, embryo viability was 85.4% (41/48) similar to that of the normoxia/Cre group (Fig. 1B). Thus, loss of viability is A1AR dependent.

We next examined the effects of 96 hours of hypoxia. Previous work examining the role of A1AR in protecting the embryo from hypoxic stress demonstrated reduced viability and increased percentage of reabsorbed embryos after 96 hours of hypoxia in the A1AR global knockout (KO) mouse model [3]. Four days of hypoxia exposure from E8.5-12.5 caused a significant decrease in embryo viability and an increase in embryo re-absorption in the cardiac specific A1AR KO mice (Fig. 1C). Compared with 72 hours, 96 hours of hypoxia had a much greater adverse effect on viability; the viability for 96 hours went from 83.8% (31/37) in room air to only 18.4% (7/38) in hypoxia (Fig. 1C).

To further define periods of vulnerability, we examined hypoxia from E10.5-12.5, 48 hours of hypoxia in older embryos also reduced viability to 50.8% (33/65) and increased re-absorption of embryos to 36.9% (24/65, Fig. 1C). This finding is in contrast to the viability observed for the 48 hours of hypoxia treatment earlier in development from E8.5-10.5 (81.3%). These observations indicate that the period of E10.5-12.5 is when embryo protection against hypoxia is most dependent on cardiac A1ARs.

Influences on cardiac development

Previous work has demonstrated that hypoxia exposure early in embryogenesis leads to growth retardation and reduced cardiac tissue growth, both of which are exacerbated by the global loss of A1ARs [3, 21]. To test if deletion of cardiac A1ARs mediated effects on embryonic and cardiac growth, we assessed the CR length of embryos following 48, 72, and 96 hours of hypoxia and cardiac tissue area after 72 hours of hypoxia. CR lengths and heart size measurements were obtained from live embryos only. Four groups of embryos were analyzed: 1) Normoxia A1ARfl/fl (Normox/Flox) dams reared in room air. 2) Normoxia A1ARfl/fl, αMHC-Cre (Normox/Cre) dams reared in room air and A1ARs deleted in cardiomyocytes. 3) Hypoxia A1ARfl/fl (Hypox/Flox) dams reared in 10% O2. 4) Hypoxia A1ARfl/fl, αMHC-Cre (Hypox/Cre), dams reared in 10% O2 and A1ARs deleted in cardiomyocytes.

After 48 hours of hypoxia from E8.5-10.5, there was no significant difference in CR lengths compared to normoxia controls. There are no differences among all four groups (Fig. 2). However, hypoxia for 48 hours from E10.5-12.5 resulted in significant embryo growth inhibition as compared to room air controls (Fig. 2). Both the Hypox/Cre and the Hypox/Flox groups were growth retarded by about 15% after 48 hours of hypoxia at these later stages, but there was no difference between these two hypoxia groups (p > 0.05; Fig. 2).
Figure 2

Hypoxia exposure for three days induces embryonic growth retardation. (A) Embryos exposed to hypoxia for 2 days in utero from E8.5-10.5 were not growth retarded compared to room air controls, but embryos exposed to hypoxia in utero from E10-12.5 exhibited significant growth retardation. Embryos exposed to hypoxia for 3 days demonstrated an even greater amount of growth retardation compared to controls. (B-E) Representative pictures of the different treatment and genotype groups after 3 days are shown. Normoxic embryos both (B) Normox/Flox and (C) Normox/Cre displayed normal morphology and growth. The hypoxic embryos (D) Hypox/Flox and (E) Hypox/Cre were significantly growth retarded, however there was no difference between Hypox/Flox and Hypox/Cre embryos. Cre/+ embryos have A1AR deleted from cardiomyocytes. *, P ≤ 0.01; **, P ≤ 0.001. Scale bar is 1 mm.

After 72 hours of hypoxia, from E8.5-11.5, both the cardiac A1AR KO embryos and the control littermates exhibited significant growth retardation, with CR length 30% less than room air controls (Fig. 2E). No specific gross morphological defects were identified in the 72 hours hypoxic embryos (Fig. 2A-D). Although both Cre and non-Cre embryos were affected by hypoxia, there were no differences in crown-rump length between the Hypox/Cre and Hypox/Flox groups after 72 hours of hypoxia (Fig. 2). This observation may be due to the fact that only live embryos were measured and some of the more severely affected embryos were not counted. This issue would affect the Cre group more, as they have a higher rate of dead and re-absorbed embryos.

When we examined heart morphology, we observed retarded heart growth in embryos lacking cardiac A1ARs under hypoxia, compared to embryos with cardiac A1ARs. Embryos exposed to hypoxia for 72 hours from E8.5-11.5 were studied as described [3]. 72 hours of exposure was chosen for this analysis, as no discernable effects on embryonic growth were seen with 48 hours (from E8.5-10.5), and 96 hours of hypoxia exposure led to greatly decreased viability.

We measured three areas of hearts to determine the effects of hypoxia and loss of cardiac expression of A1AR on the growth of the developing heart. We calculated the average area of the myocardium throughout the heart and in the AV canal region of the heart. In addition, the areas of both the AV canal and outflow tract (OFT) cardiac cushions were measured.

Our analysis demonstrated a decrease in cardiac myocardium by 25% for both total and AV canal region myocardial tissue in the Hypoxia/Flox group compared to the control Normox/Flox group (Fig. 3). The Hypox/Cre group showed an even greater reduction in size of 65% for total and 52% for AV region myocardium compared to its control group Normox/Cre (Fig 3). Histological analysis confirmed the marked decrease in size of the Hypox/Cre hearts and the disrupted morphology compared to the Hypox/Flox hearts, which demonstrate reduced size but display normal overall morphology similar to room air controls (Fig. 3A-D). The cardiac cushions, both AV and OFT, were also analyzed, and the Hypox/Flox group had a similar, 30% and 26%, respectively, decrease in area as seen for myocardial analysis tissue (Fig. 3E).
Figure 3

Loss of A1ARs in cardiac tissue leads to reduced heart tissue under hypoxic conditions. Pregnant dams were exposed to hypoxia for 3 days from E8.5-E11.5 before embryos were collected. (A) Using Image-Pro Plus software, the cross-sectional area of the ventricle throughout the heart and at the level of the AV canal was measured as well as the area of the AV and OFT cardiac cushions. Hypoxia caused a 25% decrease in the area of myocardial tissue both overall and at the level of the AV canal in the Hypox/Flox group. In the Hypox/Cre group, with A1AR deleted from cardiomyocytes, the decrease in area was more severe, 65% overall and 52% at the level of the AV canals. The AV canal cushions (30%) and OFT cushions (26%) were reduced in size in the Hypox/Flox group. Both room air groups (B) Normox/Flox and (C) Normox/Cre exhibited normal morphology and size. (D) Hypox/Flox hearts were normal in morphology but truncated in size, where as the (E) Hypox/Cre hearts displayed disrupted morphology and severely reduced size. *, P ≤ 0.05; **, P ≤ 0.01 by student's t-test. Scale bar is 200 μm.

Because of decreased viability of the Hypox/Cre group, fewer hearts were analyzed by this method, and there was not enough tissue to accurately measure the AV canal and OFT cushions. These data indicate that although the overall growth inhibition of the whole embryo observed with hypoxia exposure is not exacerbated by the loss of cardiac A1AR expression, the growth and morphology of the heart is adversely affected by hypoxia to a greater degree when A1ARs were deleted from cardiomyocytes.

96 hours of hypoxia caused an even greater reduction in growth but few embryos were collected and measured. The average crown rump length of Hypox/Flox embryos exposed to hypoxia for 96 hours, from E8.5-12.5, was decreased by 34% to 5.7 mm (± 0.29, N = 5), which is extremely significant compared to 8.6 mm for Normox/Flox embryos (P ≤ 3.7 × 10-6). There were not enough 96 hours Hypox/Cre embryos to analyze for crown-rump length. These data indicate that hypoxia inhibits overall embryonic growth but the loss of cardiac A1AR expression does not exacerbate hypoxic growth inhibition.

A1AR-mediated gene expression

Microarray analysis was performed on RNA collected from hearts following 24 hours of hypoxia exposure to identify molecular pathways involved in A1AR-mediated embryonic protection. Genes with altered expression in A1AR-deleted hearts were involved in biological pathways important for hypoxia responsiveness and normal heart development (Table 1).
Table 1

Pathways affect by Cardiac A1AR loss.

Cellular Process/Pathway

# of Genes

P Value

Transcription/Role of Akt in hypoxia induced HIF1 activation

7 of 26

4.75E-04

Cytoskeleton remodeling/Regulation of actin cytoskeleton by Rho GTPases

6 of 23

1.47E-03

Glycolysis and gluconeogenesis (short map)

8 of 37

9.28E-04

Development/EPO-induced PI3K/AKT pathway and Ca(2+) influx

7 of 32

1.81E-03

Cytoskeleton remodeling Role of PKA in cytoskeleton reorganization

6 of 31

7.28E-03

Two sets of genes were identified to have altered expression with the loss of A1AR gene expression: In the first set, gene expression was influenced by hypoxia when A1ARs were not expressed in the cardiomyocytes (Table 2). The second set of genes had altered expression with the loss of A1AR expression either under hypoxic or normoxic conditions (Table 3). Genes with altered expression include, myosin heavy chain alpha (Myh6) and myosin heavy chain beta (Myh7), both of which are important for cardiac development and they are expressed throughout the heart early in development but become more restricted as development continues [25]. The expression of these myosin genes was disrupted by the loss of cardiac A1ARs. Myh6, which normally decreases at E10.5, was up regulated in hearts without A1ARs (Table 3). In comparison, Myh7 was down regulated in A1AR deleted hearts compared to hearts with A1AR expression (Table 3).
Table 2

Genes Regulated by Hypoxia and A1AR.

Probe ID

Gene

Hypox/Flox vs. Normox/Flox

P-Values

Hypox/Cre vs. Normox/Cre

P-Values

Hypoxia, A1AR, or Cardiac Related

ILMN_2675874

Alas2

1.91597

2.06E-06

-3.18773

2.30E-08

Hypoxia inducible

ILMN_1219154

Mt2

1.63401

0.000359711

-2.98376

1.07E-06

Hypoxia

ILMN_2596522

Mt1

2.56154

0.000118805

-2.50707

0.000139519

Hypoxia

ILMN_1250195

Ndrg1

1.9098

5.38E-06

-2.29342

8.07E-07

Hypoxia inducible

ILMN_2998934

Cited4

1.69681

8.45E-06

-2.17613

4.47E-07

Hypoxia

ILMN_2606746

Car2

1.5989

0.00168738

-2.14858

6.64E-05

Hypoxia

ILMN_2881620

Nfe2

1.87921

1.62E-06

-1.93972

1.11E-06

Cardiac

ILMN_2757966

Cxcl4

2.27996

1.05E-05

-1.89452

6.70E-05

Hypoxia inducible

ILMN_2652909

Ddit3

1.88154

0.00576158

-1.72809

0.0120442

Hypoxia inducible

ILMN_2829594

Hspa1a

2.36474

1.80E-05

-1.61118

0.00104107

Hypoxia, Cardiac

ILMN_2739544

Stc2

1.92291

2.06E-05

-1.5783

0.000261328

Hypoxia

ILMN_2605819

Egln3

2.16962

1.28E-05

-1.49541

0.00117156

Hypoxia inducible

ILMN_2643513

Asns

1.63692

5.53E-05

-1.47277

0.00029547

Hypoxia inducible

ILMN_2616565

Slc2a3

2.08188

0.000497509

-1.42853

0.0256759

Hypoxia inducible

ILMN_1249378

Bhlhb2

1.89041

4.28E-05

-1.41041

0.00250315

Hypoxia inducible

ILMN_1252762

Trib3

1.5549

2.61E-05

-1.14939

0.0267126

Hypoxia inducible

ILMN_2993109

Ddit4

1.53476

0.000963138

-1.14033

0.158638

Hypoxia inducible

ILMN_2747959

Dcn

-1.59119

2.13E-06

-1.02086

0.608063

Hypoxia inducible

ILMN_1234662

Mb

-1.51848

0.00354732

-1.00718

0.946075

Hypoxia inducible

ILMN_2632940

Sumo1

1.59231

1.31E-05

-1.00062

0.990303

Hypoxia, A1AR, Cardiac

ILMN_3001540

Lum

-1.64593

4.50E-05

1.15664

0.0484385

Hypoxia, Cardiac

ILMN_2639036

Hspd1

1.61697

0.000950629

1.1836

0.112501

Hypoxia, Cardiac

ILMN_2763002

Eno2

1.72159

4.71E-05

1.22827

0.0171715

Hypoxia

ILMN_2677662

Hspb7

-1.89271

6.57E-05

1.59123

0.000573211

Cardiac

Table 3

Genes Regulated by A1AR.

Probe ID

Symbol

Hypox/Cre vs. Hypox/Flox

P-Values

Normox/Cre vs Normox/Flox

P-Values

Hypoxia, A1AR, or Cardiac Related

ILMN_2665239

Myh7

-1.97085

0.000711557

-1.72806

0.0026561

Cardiac

ILMN_2697652

Chd4

-1.8584

1.21E-05

-1.60686

8.43E-05

Cardiac

ILMN_2610234

Il15

-1.83954

3.66E-05

-1.39673

0.00201565

Hypoxia, Cardiac

ILMN_2870672

Fbln1

-1.51609

0.000181497

-1.507

0.00020053

Cardiac

ILMN_2489448

Sobp

-1.50775

0.000618205

-1.54295

0.000432693

Hypoxia

ILMN_2655260

Ptp4a3

1.51792

0.00020671

1.95951

6.64E-06

Cardiac

ILMN_2967266

Fxyd5

1.52066

0.000483488

1.53701

0.000409621

Hypoxia

ILMN_3155180

Itpr2

1.52132

0.0152983

1.57414

0.0105084

Cardiac

ILMN_2711267

Krt18

1.63969

0.000254672

1.58581

0.000406559

Cardiac

ILMN_3139103

Adam15

1.68522

0.000507188

1.48327

0.00285996

Cardiac

ILMN_2475156

Xist

1.98732

0.00101892

2.03269

0.00083102

Hypoxia, Cardiac

ILMN_1213376

Cfl1

2.02757

8.54E-08

2.19178

3.76E-08

Cardiac

ILMN_2640008

Myh6

2.0374

0.00470426

1.59291

0.0349642

Cardiac

ILMN_2761594

Cirbp

2.39335

1.52E-07

1.79484

3.32E-06

Hypoxia, Cardiac

Discussion

A1ARs are not critical for normal embryonic or cardiac development in normoxic conditions, as deletion of A1ARs throughout the embryo does not result in birth defects or growth retardation under normal circumstances [15]. During hypoxia however, A1ARs play an essential role in protecting the embryo [3]. Studying murine embryos lacking A1ARs in the heart, we now identify the heart as the critical region where A1ARs act to confer embryo protection.

Previous studies indicate that embryo viability was greatly decreased after 96 hours of hypoxia when A1AR was deleted globally [3]. In the current studies, we examined the viability of cardiac-deleted A1AR mice after 48, 72, and 96 hours of hypoxia exposure (10% O2). We found that after 48 hours of hypoxia from E8.5-10.5, there was no difference in viability between normoxia and hypoxia treated embryos. Since the heart becomes more important for nutrient delivery and embryo survival as embryogenesis proceeds, we examined whether 48 hours of exposure later in development, from E10.5-12.5, could affect embryonic viability. Two days later in development, the embryo is more susceptible to hypoxic stress, as embryos exposed to hypoxia from E10.5-12.5 had a 40% decrease in viability compared to room air controls.

After 72 hours of hypoxia, from E8.5-11.5, we observed a dramatic decrease in embryo viability compared to room air controls. We were able to determine the genotype of live embryos by testing yolk sac DNA, but we were not able to genotype all the dead and reabsorbed embryos. Since we were unable to determine that only Cre-expressing embryos were dying, we mated A1ARfl/fl mice with each other. These mice did not express Cre-recombinase, therefore cardiac A1AR expression was normal. Under hypoxic conditions, the viability of non-Cre litters was the same as room air control litters, indicating that the loss in viability observed in the cardiac A1AR knockout litters was due to the loss of A1AR and not hypoxic exposure alone. Finally, we examined embryonic viability after 96 hours of hypoxia exposure, from E8.5-12.5, in this case the viability was much less than the 72-hour hypoxia group with less than 1 in 5 embryos surviving. These results are similar to that observed with the global knockout of A1AR after 96 hours of hypoxia [3]. Collectively these data indicate that older embryos are more susceptible to hypoxic insults, and cardiac A1ARs are critical in protecting embryos from hypoxic conditions.

Next, we analyzed embryonic growth of all live embryos collected by measuring the crown-rump length. After 48 hours of treatment between E8.5-10.5, there were no differences in CR lengths, the same result as that seen with embryo viability at this stage. However, hypoxic exposure for 48 hours later in development caused a small but significant decrease in embryo size compared to room air controls, but no difference between the hypoxia groups with and without cardiac A1AR expression was observed. Growth inhibition was also analyzed after 72 hours of hypoxia, from E8.5-11.5, embryos were more severely growth retarded than the later 48 hours of hypoxia exposure but again no differences between the hypoxia exposed groups were observed. Due to the poor viability of 96 hours hypoxia exposed embryos, we could not get an accurate measure of the crown-rump length. These data are consistent with results for non-transgenic C57Bl/6 mice exposed to hypoxia for 72 hours, which showed a 24% growth inhibition [3].

Although cardiac A1ARs are critical for viability during hypoxic stress, their loss does not increase the amount of growth inhibition seen with hypoxia treatment. The growth inhibition observed in the cardiac A1AR knockout mice is consistent with that in wildtype mice (C57Bl/6 strain) exposed to hypoxia [3]. We previously reported that global loss of A1ARs affects overall embryonic growth above and beyond what is observed in non-transgenic mice exposed to hypoxia for 96 hours [3]. However, that previous report only classified embryos into two categories, collected embryos and re-absorbed embryos, and did not make a determination of whether the collected embryos were alive or dead. This current report classifies embryos into three categories, live, dead, and re-absorbed. So when embryonic growth, as measured by crown-rump length, is compared only between live embryos of the different genotypes, the loss of cardiac A1AR does not exacerbate hypoxia growth inhibition. These data indicate that hypoxia growth inhibition is a general effect of hypoxia and that reduced viability in hypoxia is specific for the loss of A1AR in the heart.

The loss of cardiac A1ARs has severe adverse effects on heart development. 72 hours of hypoxia exposure from E8.5-11.5 causes a 65% decrease in myocardial tissue in hearts not expressing A1ARs compared to only a 25% decrease in cardiac tissue in hearts expressing A1ARs. There was also a decrease in the size of the cardiac cushions following hypoxia in hearts expressing A1ARs, however hearts without A1AR expression were too small and malformed to measure the cardiac cushion tissue accurately. These data indicate that the loss of A1ARs in cardiomyocytes is having severe adverse effects on cardiac development when the embryo is exposed to hypoxic conditions. Reduced cardiac tissue could be leading to abnormal function of the embryonic heart and that maybe why there is reduced viability at the later stages of development when cardiac function becomes critical for embryonic survival.

Because of the small sizes of the embryos studied, it was not possible for us to directly assess levels of the other adenosine receptors in the myocardium. However, during early embryogenesis, only A1ARs are known to be expressed in the heart [12]. In studies of global A1AR-/- mice, changes in the expression of other adenosine receptors have not been observed [15]. Due to technical limitations, it was also not possible for us to assess adenosine levels in the normoxic or hypoxic embryos.

Gene expression analysis revealed sets of genes in the heart that are misregulated during hypoxia exposure when A1ARs are not expressed. For example, there are genes that are misregulated with the loss of A1AR expression either in hypoxic or normoxic conditions, such as Myh6 and Myh7. Gene expression data thus indicates that A1AR loss could adversely affect cardiac development by altering the expression of cardiac genes related to cardiac function, leaving the embryo susceptible to hypoxic stress.

Further analysis reveals another set of genes that are miss-regulated in the A1AR deleted hearts. These genes are normally up regulated in response to hypoxia to protect the heart from damage including heat shock proteins 60 (Hspd1) and 70 (Hspa1a), and Metallothionein (MT) 1 and 2, but in the cardiac A1AR-/- hearts their expressions are down regulated or not changed with hypoxia treatment [2629]. A1AR signaling was demonstrated to up-regulate MT levels during ischemia-reperfusion (I/R) and may mediate the cardioprotective effects of A1AR agonist preconditioning [27]. MT has been reported to stabilize HIF protein and this may be a mechanism of cardio protection [30], and relates to the fact that we demonstrated less stabilized HIF protein during hypoxia in the global knockout A1AR embryos [3].

These data indicates that the mechanism by which A1AR mediates cardio and embryonic protection during hypoxic exposure of embryos in utero may be similar to the mechanisms by which A1AR signaling leads to cardioprotection from I/R injury in adult hearts and may be related to HIF signaling. Gene expression analysis also indicates that the loss of A1AR signaling may leave the heart more susceptible to hypoxia-induced damage since increased expression of the genes associated with protection against hypoxia were not observed.

Conclusions

Our findings confirm that A1AR expression is important for embryonic survival during hypoxic stress and that the A1ARs expressed in the heart mediate this protection. Disrupted cardiac development during hypoxia exposure in cardiac A1AR deleted embryos leads to decreased embryonic viability at stages where cardiac function is critical for embryonic survival.

Abbreviations

(A1ARs): 

Adenosine A1 receptors

(E): 

embryonic day

(αMHC): 

alpha-myosin heavy chain

(1-3: 

dipropylcyclopentyl xanthine): DPCPX

(CR): 

crown-rump

(AV): 

atrioventricular

(OFT): 

outflow tract

(Myh6): 

myosin heavy chain alpha

(Myh7): 

myosin heavy chain beta

(MT): 

Metallothionein

(HIF1α): 

hypoxia-inducible factor 1α.

Declarations

Acknowledgements

This work was supported by U. S. National Institutes of Health grant R01HD058086 (S. A. R.), the Charles H. Hood Foundation (S. G.), and the Yale Diabetes Endocrinology Research Center (C. C. W.). We thank Sarah Renzi and Carolyn McClaskey for technical assistance.

Authors’ Affiliations

(1)
Section of Developmental Endocrinology and Biology, Yale Child Health Research Center, Department of Pediatrics, Yale University School of Medicine
(2)
Department of Psychiatry, University of Texas Southwestern Medical Center and Dallas Veterans Administration Medical Center

References

  1. Zhang L: Prenatal hypoxia and cardiac programming. J Soc Gynecol Investig. 2005, 12: 2-13. 10.1016/j.jsgi.2004.09.004.View ArticlePubMedGoogle Scholar
  2. Ghatpande SK, Billington CJ, Rivkees SA, Wendler CC: Hypoxia induces cardiac malformations via A1 adenosine receptor activation in chicken embryos. Birth Defects Res A Clin Mol Teratol. 2008, 82: 121-30. 10.1002/bdra.20438.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Wendler CC, Amatya S, McClaskey C, Ghatpande S, Fredholm BB, Rivkees SA: A1 adenosine receptors play an essential role in protecting the embryo against hypoxia. Proc Natl Acad Sci USA. 2007, 104: 9697-702. 10.1073/pnas.0703557104.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Sharma SK, Lucitti JL, Nordman C, Tinney JP, Tobita K, Keller BB: Impact of hypoxia on early chick embryo growth and cardiovascular function. Pediatr Res. 2006, 59: 116-20. 10.1203/01.pdr.0000191579.63339.90.View ArticlePubMedGoogle Scholar
  5. Tintu A, Rouwet E, Verlohren S, Brinkmann J, Ahmad S, Crispi F, van Bilsen M, Carmeliet P, Staff AC, Tjwa M, Cetin I, Gratacos E, Hernandez-Andrade E, Hofstra L, Jacobs M, Lamers WH, Morano I, Safak E, Ahmed A, le Noble F: Hypoxia induces dilated cardiomyopathy in the chick embryo: mechanism, intervention, and long-term consequences. PLoS One. 2009, 4: e5155-10.1371/journal.pone.0005155.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Jensen GM, Moore LG: The effect of high altitude and other risk factors on birthweight: independent or interactive effects?. Am J Public Health. 1997, 87: 1003-7. 10.2105/AJPH.87.6.1003.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Fei X, Yue-Sheng H, Dong-Xia Z, Zhi-Gang C, Jia-Ping Z, Qiong Z: Adenosine A1 receptor activation reduces mitochondrial permeability transition pores opening in hypoxic cardiomyocytes. Clin Exp Pharmacol Physiol. 2010, 37: 343-9. 10.1111/j.1440-1681.2009.05300.x.View ArticleGoogle Scholar
  8. Ijzerman A, van Rhee AM: Modulators of adenosine uptake, release, and inactivation. Purinergic Approaches in Experimental Therapeutics. Edited by: Jacobson KA, Jarvis MF. 1997, New York: Wiley-Liss, 129-148.Google Scholar
  9. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M: Nomenclature and classification of purinoceptors. Pharmacol Rev. 1994, 46: 143-56.PubMedGoogle Scholar
  10. Olah ME, Stiles GL: Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol. 1995, 35: 581-606. 10.1146/annurev.pa.35.040195.003053.View ArticlePubMedGoogle Scholar
  11. Hofman PL, Hiatt K, Yoder MC, Rivkees SA: A1 adenosine receptors potently regulate heart rate in mammalian embryos. Am J Physiol. 1997, 273: R1374-80.PubMedGoogle Scholar
  12. Rivkees SA: The ontogeny of cardiac and neural A1 adenosine receptor expression in rats. Brain Res Dev Brain Res. 1995, 89: 202-213. 10.1016/0165-3806(95)00120-3.View ArticlePubMedGoogle Scholar
  13. Matherne GP, Linden J, Byford AM, Gauthier NS, Headrick JP: Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc Natl Acad Sci USA. 1997, 94: 6541-6546. 10.1073/pnas.94.12.6541.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Willems L, Reichelt ME, Molina JG, Sun CX, Chunn JL, Ashton KJ, Schnermann J, Blackburn MR, Headrick JP: Effects of adenosine deaminase and A1 receptor deficiency in normoxic and ischaemic mouse hearts. Cardiovasc Res. 2006, 71: 79-87. 10.1016/j.cardiores.2006.03.006.View ArticlePubMedGoogle Scholar
  15. Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escorihuela RM, Fernandez-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, Hardemark A, Betsholtz C, Herlenius E, Fredholm BB: Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA. 2001, 98: 9407-12. 10.1073/pnas.161292398.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Conway SJ, Kruzynska-Frejtag A, Kneer PL, Machnicki M, Koushik SV: What cardiovascular defect does my prenatal mouse mutant have, and why?. Genesis. 2003, 35: 1-21. 10.1002/gene.10152.View ArticlePubMedGoogle Scholar
  17. Agah R, Frenkel PA, French BA, Michael LH, Overbeek PA, Schneider MD: Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J Clin Invest. 1997, 100: 169-79. 10.1172/JCI119509.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Scammell TE, Arrigoni E, Thompson MA, Ronan PJ, Saper CB, Greene RW: Focal deletion of the adenosine A1 receptor in adult mice using an adeno-associated viral vector. J Neurosci. 2003, 23: 5762-70.PubMedGoogle Scholar
  19. Heine HL, Leong HS, Rossi FM, McManus BM, Podor TJ: Strategies of conditional gene expression in myocardium: an overview. Methods Mol Med. 2005, 112: 109-54. full_text.View ArticlePubMedGoogle Scholar
  20. Turner C, Seli M, Ment L, Stewart WA, Yan H, Johansson B, Fredholm B, Blackburn M, RIvkees S: A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc Natl Acad Sci USA. 2003, 100: 11718-11722. 10.1073/pnas.1931975100.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Wendler CC, Busovsky-McNeal M, Ghatpande S, Kalinowski A, Russell KS, Rivkees SA: Embryonic caffeine exposure induces adverse effects in adulthood. FASEB J. 2009, 23: 1272-8. 10.1096/fj.08-124941.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Koos BJ, Doany W: Role of plasma adenosine in breathing responses to hypoxia in fetal sheep. J Dev Physiol. 1991, 16: 81-5.PubMedGoogle Scholar
  23. Bae S, Xiao Y, Li G, Casiano CA, Zhang L: Effect of maternal chronic hypoxic exposure during gestation on apoptosis in fetal rat heart. Am J Physiol Heart Circ Physiol. 2003, 285: H983-90.View ArticlePubMedGoogle Scholar
  24. Wendler CC, Rivkees SA: Sphingosine-1-phosphate inhibits cell migration and endothelial to mesenchymal cell transformation during cardiac development. Dev Biol. 2006, 291: 264-77. 10.1016/j.ydbio.2005.12.013.View ArticlePubMedGoogle Scholar
  25. Weiss A, Leinwand LA: The mammalian myosin heavy chain gene family. Annu Rev Cell Dev Biol. 1996, 12: 417-39. 10.1146/annurev.cellbio.12.1.417.View ArticlePubMedGoogle Scholar
  26. Xue W, Liu Q, Cai L, Wang Z, Feng W: Stable overexpression of human metallothionein-IIA in a heart-derived cell line confers oxidative protection. Toxicol Lett. 2009, 188: 70-6. 10.1016/j.toxlet.2009.03.007.View ArticlePubMedGoogle Scholar
  27. Xie C, Ran K, Liu J, Xu J, Chang Y: Metallothionein mediates cardioprotection induced by delayed preconditioning with adenosine A1 receptor agonist in rabbits. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009, 34: 603-7.PubMedGoogle Scholar
  28. Chen HS, Wu TE, Juan CC, Lin HD: Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats. J Endocrinol. 2009, 200: 151-7. 10.1677/JOE-08-0387.View ArticlePubMedGoogle Scholar
  29. Hampton CR, Shimamoto A, Rothnie CL, Griscavage-Ennis J, Chong A, Dix DJ, Verrier ED, Pohlman TH: HSP70.1 and -70.3 are required for late-phase protection induced by ischemic preconditioning of mouse hearts. Am J Physiol Heart Circ Physiol. 2003, 285: H866-74.View ArticlePubMedGoogle Scholar
  30. Kojima I, Tanaka T, Inagi R, Nishi H, Aburatani H, Kato H, Miyata T, Fujita T, Nangaku M: Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int. 2009, 75: 268-77. 10.1038/ki.2008.488.View ArticlePubMedGoogle Scholar

Copyright

© Wendler et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement